Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo

J Clin Invest. 1998 Mar 1;101(5):993-1000. doi: 10.1172/JCI1833.

Abstract

The binding of 125I-factor Xa to human aortic smooth muscle cell (SMC) monolayers was studied. At 4 degreesC, 125I-factor Xa bound to a single class of binding sites with a dissociation constant value of 3.6+/-0.7 nM and a binding site density of 11,720+/-1,240 sites/cell (n = 9). 125I-factor Xa binding was not affected by factor X, thrombin, or by DX9065, a direct inhibitor of factor Xa, but was inhibited by factor Xa (IC50 = 5.4+/-0.2 nM; n = 9) and by antibodies specific for the effector cell protease receptor 1 (EPR-1), a well-known receptor of factor Xa on various cell types. A factor X peptide duplicating the inter-EGF sequence Leu83-Leu88-(Gly) blocked the binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 = 110+/-21 nM). Factor Xa increased phosphoinositide turnover in SMCs and when added to SMCs in culture was a potent mitogen. These effects were inhibited by DX9065 and by antibodies directed against EPR-1 and PDGF. Increased expression of EPR-1 was identified immunohistochemically on SMCs growing in culture and in SMCs from the rabbit carotid artery after vascular injury. When applied locally to air-injured rabbit carotid arteries, antibodies directed against EPR-1 (100 mug/ artery) strongly reduced myointimal proliferation 14 d after vascular injury (65-71% inhibition, P < 0.01). DX9065 (10 mg/kg, subcutaneous) inhibited myointimal proliferation significantly (43% inhibition, P < 0.05). These findings indicate that SMCs express functional high affinity receptors for factor Xa related to EPR-1, which may be of importance in the regulation of homeostasis of the vascular wall and after vascular injury.

MeSH terms

  • Animals
  • Antibodies, Blocking / immunology
  • Blotting, Western
  • Carotid Arteries / cytology
  • Carotid Arteries / metabolism
  • Carotid Artery Injuries
  • Cells, Cultured
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / injuries
  • Endothelium, Vascular / metabolism*
  • Epidermal Growth Factor / metabolism
  • Factor X / pharmacology
  • Factor Xa / metabolism*
  • Factor Xa / pharmacology
  • Factor Xa Inhibitors
  • Hemostatics / pharmacology
  • Homeostasis
  • Humans
  • Immunohistochemistry
  • Inhibitor of Apoptosis Proteins
  • Muscle, Smooth / cytology
  • Muscle, Smooth / metabolism*
  • Naphthalenes / pharmacology
  • Peptides / metabolism
  • Phosphatidylinositols / metabolism
  • Platelet-Derived Growth Factor / immunology
  • Propionates / pharmacology
  • Protein Binding
  • Rabbits
  • Receptors, Cell Surface / immunology
  • Receptors, Cell Surface / metabolism*
  • Serine Proteinase Inhibitors
  • Survivin
  • Thrombin / pharmacology

Substances

  • (2S)-2-(4-(((3S)-1-acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphtyl)propanoic acid
  • Antibodies, Blocking
  • BIRC5 protein, human
  • Factor Xa Inhibitors
  • Hemostatics
  • Inhibitor of Apoptosis Proteins
  • Naphthalenes
  • Peptides
  • Phosphatidylinositols
  • Platelet-Derived Growth Factor
  • Propionates
  • Receptors, Cell Surface
  • Serine Proteinase Inhibitors
  • Survivin
  • Epidermal Growth Factor
  • Factor X
  • Thrombin
  • Factor Xa